Dr. Jessica A. Haffajee, MD

Dr. Haffajee practices at The Cancer Center at Beth Israel Deaconess Medical Center - Physical Therapy - HOPD in Needham, Massachusetts.

Dr. Haffajee's NPI, 1952406340, was assigned on September 13, 2006. Dr. Haffajee graduated from Perelman School of Med at the University of Pennsylvania in 2004. Dr. Haffajee holds Massachusetts license 230227.

Dr. Haffajee's primary practice is The Cancer Center at Beth Israel Deaconess Medical Center - Physical Therapy - HOPD, at 148 Chestnut St, Needham, MA 02492.

Dr. Haffajee's primary practice is The Cancer Center at Beth Israel Deaconess Medical Center - Physical Therapy - HOPD in Needham, Massachusetts. Dr. Haffajee is also affiliated with Beth Israel Deaconess Hospital-Needham. The medical group on file is Harvard Medical Faculty Physicians at Beth Israel Deaconess Medical Center (HMFP). Dmand AI also links Dr. Haffajee to 3 more hospitals and 1 group practice or clinic, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Haffajee practices, 6 sites in all. Vendor and product names are available with a free account.

Cardiovascular disease is Dr. Haffajee's primary specialty in the NPI Registry, under taxonomy code 207RC0000X. Dr. Haffajee is licensed in Massachusetts.

CMS data shows 2,400 Medicare services from Dr. Haffajee across 16 procedure codes in 2024, for 1,064 Medicare patients. Medicare paid $130,556 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 1,064 Medicare patients who saw Dr. Haffajee in 2024. The largest group is 75 to 84, with 408 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 13% are also on Medicaid. Their average risk score is 1.58, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Haffajee's median patient age at 76, with 57% women.

In 2024, Dr. Haffajee wrote 3,831 Medicare Part D claims for 613 patients. 80% of them were for generic drugs. CMS names the drug for 3,650 of them, across 34 drugs with 11 or more claims each, at $1,626,357 in total drug cost. In 2023, CMS named 2,688 claims across 28 drugs.

Dr. Haffajee accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Haffajee as offering telehealth.

Dmand AI links 2 papers to Dr. Haffajee in 2010. 2010 was the busiest year, with 2. Dr. Haffajee's most frequent co-author is Ayan R. Patel, MD.

CMS Open Payments shows 23 general payments to Dr. Haffajee from 8 drug and device companies from 2017 to 2025. Food and beverage make up the largest share, 100% of the total. Novartis Pharmaceuticals Corporation paid the most, $201.

Dr. Haffajee graduated from Perelman School of Med at the University of Pennsylvania in 2004.